Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function

Hypertension Research

Volumn 31, Issue 8, 2008, Pages 1603-1610

  Morimoto, Satoshi ^a,b   Maki, Kei ^a   Aota, Yasuko ^b   Sakuma, Takao ^b   Iwasaka, Toshiji ^b  

^a Ohmihachiman City Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin I converting enzyme inhibitor; Angiotensin receptor blocker; Calcium antagonist; Essential hypertension; Vascular endothelial dysfunction

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PERINDOPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; MONOTHERAPY; MORNING DOSAGE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 55449087873     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1603     Document Type: Article

References (51)

1. Mogensen CE, Neldam S, Tikkanen I, et al: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminemia, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminemia (CALM) study. BMJ 2000; 321: 1440-1444.
2. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63: 1874-1880.
3. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100.
4. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18: 89-95.
5. Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25.
6. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
7. Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002; 20: 125-130.
8. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D: Dual renin-angitensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 1020-1025.
9. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
10. McMurray JJ, Ostergren J, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
11. Cheetham C, O'Driscoll G, Stanton K, et al: Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci (Lond) 2001; 100: 13-17.
12. Higashi Y, Sasaki S, Nakagawa K, et al: Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001; 37: 863-870.
13. Okuro M, Morimoto S, Takahashi T, et al: Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. Hypertens Res 2006; 29: 655-663.
14. Anderson TJ, Elstein E, Haber H, Charbonneau F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-66.
15. Morimoto S, Yano Y, Maki K, Sawada K: Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567-572.
16. Mitchell GF, Dunlap ME, Warnica W, et al, Prevention of events with Angiotensin-Converting Enzyme Inhibition Investigators: Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007; 49: 1271-1277.
17. ω-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002; 40: 789-800.
18. Corretti MC, Anderson TJ, Benjamin EJ, et al, International Branchial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-265.
19. Oshima T, Ozono R, Yano Y, et al: Beneficial effect of Ttype calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 2005; 28: 889-894.
20. Munakata M, Nunokawa T, Yoshinaga K, Toyota T: Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension.a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 2006; 29: 515-521.
21. Yufu K, Tahakashi N, Hara M, Saikawa T, Yoshima Hironobu Y: Measurement of the brachial-ankle pulse wave velocity and flow-mediated dilatation in young, healthy smokers. Hypertens Res 2007; 30: 607-612.
22. Carson PE: Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 2000; 140: 361-366.
23. Struckman DR, Rivey MP: Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure. Ann Pharmacother 2001; 35: 242-248.
24. Finnegan PM, Gleason BL: Combination ACE inhibitors and angiotensin II receptor blockers for hypertension. Ann Pharmacother 2003; 37: 886-889.
25. Van de Val RMA, van Veldhuisen DJ, van Gilst WH, Voors AA: Addition of an angiotensin receptor blocker to fulldose ACE-inhibition: controversial or common sense? Eur Heart J 2005; 26: 2361-2367.
26. Richer C, Bruneval P, Menard J, Giudicelli JF: Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 1998; 31: 692-698.
27. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP: Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1207-1215.
28. Funabiki K, Onishi K, Dohi K, et al: Combined angiotensin receptor blocker and ACE-inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. Am J Physiol Heart Circ Physiol 2004; 287: H2487-H2492.
29. Kitakaze M, Asanuma H, Funaya H, et al: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 2002; 40: 162-166.
30. Yagi S, Morita T, Katayama S: Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004; 27: 129-135.
31. Vanhoutte PM, Mombouli JV: Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 1996; 39: 229-238.
32. Luscher TF, Barton M: Biology of the endothelium. Clin Cardiol 1997; 20 (11 Suppl 2): II-3-II-10.
33. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
34. ENCORE Investigators: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107: 422-428.
35. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M: A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 1999; 33: 242-249.
36. Kitakaze M, Asanuma H, Takashima S, et al: Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000: 25; 101: 311-317.
37. Hasebe N, Kikuchi K, NICE Combi Study Group: Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445-453.
38. Calermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
39. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-1474.
40. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-2516.
41. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM: Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 1994; 330: 1036-1040.
42. Frick M, Alber HF, Weidinger F: Endothelial function in a large community. Circulation 2004; 110: e24.
43. Anderson TJ, Uehata A, Gerhard MD, et al: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.
44. Ogawa S, Takeuchil, Mori T, et al: Effects of monotherapy of temocapril or candsartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007; 30: 325-334.
45. Lehmann ED: Clinical value of aortic pulse-wave velocity measurement. Lancet 1999; 354: 528-529.
46. Nakamura U, Iwase M, Nohara S, Kanai H, Ichikawa K, Iida M: Usefulness of brachial-ankle pulse wave velocity measurement: correlation with abdominal aortic calcification. Hypertens Res 2003; 26: 163-167.
47. Yamashina A, Tomiyama H, Arai T, et al: Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26: 615-622.
48. Sawabe M, Takahashi R, Matsushita S, et al: Aortic pulse wave velocity and the degree of atherosclerosis in the elderly: a pathological study based on 304 autopsy cases. Atherosclerosis 2005; 179: 345-351.
49. Anan F, Takahashi N, Ooie T, et al: Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005; 61: 353-359.
50. Nissen SE, Tuzcu EM, Libby P, et al, CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
51. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.